Skip to content
Anlotinib
Anlotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
319 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022891651115979
Small cell lung carcinomaD05575221421219
SarcomaD01250931331118
Head and neck neoplasmsD006258112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C807161122
Liver neoplasmsD008113EFO_1001513C22.01122215
Colorectal neoplasmsD01517929210
Triple negative breast neoplasmsD0647262518
Stomach neoplasmsD013274EFO_0003897C1616128
Ovarian neoplasmsD010051EFO_0003893C561617
Endometrial neoplasmsD016889EFO_00042302617
Uterine cervical neoplasmsD00258322115
Thyroid neoplasmsD013964EFO_0003841515
Biliary tract neoplasmsD001661C24.9112
Show 7 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.90410314
Esophageal squamous cell carcinomaD000077277819
GlioblastomaD005909EFO_0000515277
Nasopharyngeal neoplasmsD009303277
Breast neoplasmsD001943EFO_0003869C5066
ImmunotherapyD007167155
Pancreatic neoplasmsD010190EFO_0003860C25335
AdenocarcinomaD0002302315
Female genital neoplasmsD0058331415
Neoplasms by siteD00937144
Show 51 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K7711
Multiple myelomaD009101C90.011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ChemoradiotherapyD05924811
Small cell carcinomaD01828811
Aggressive fibromatosisD01822211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameANLOTINIB
INNcatequentinib
Description
Anlotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Identifiers
PDB
CAS-ID1058156-90-3
RxCUI
ChEMBL IDCHEMBL4303201
ChEBI ID
PubChem CID
DrugBank
UNII IDGKF8S4C432 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KDR
KDR
FLT4
FLT4
FGFR1
FGFR1
FLT1
FLT1
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,917 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
152 adverse events reported
View more details